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Background: Numerous analogs of the antitumor agents epothilones A and B
have been synthesized in search of better pharmacological pro¢les. Insights into
the structure^activity relationships within the epothilone family are still needed
and more potent and selective analogs of these compounds are in demand, both
as biological tools and as chemotherapeutic agents, especially against drug-
resistant tumors.
Results: A series of pyridine epothilone B analogs were designed, synthesized
and screened. The synthesized compounds exhibited varying degrees of tubulin
polymerization and cytotoxicity properties against a number of human cancer cell
lines depending on the location of the nitrogen atom and the methyl substituent
within the pyridine nucleus.
Conclusions: The biological screening results in this study established the
importance of the nitrogen atom at the ortho position as well as the bene¢cial
effect of a methyl substituent at the 4- or 5-position of the pyridine ring. Two
pyridine epothilone B analogs (i.e. compounds 3 and 4) possessing higher
potencies against drug-resistant tumor cells than epothilone B, the most powerful
of the naturally occurring epothilones, were identi¢ed.
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Introduction
The clinical success of paclitaxel (PTX) and docetaxel in
the treatment of cancer has prompted a worldwide search
for compounds with a similar mechanism of action but
improved characteristics. The low aqueous solubility of
PTX and the development of clinical drug resistance,
mediated by both the overexpression of P-glycoprotein
(P-pg) and the presence of L-tubulin mutations [1] are
factors that hamper its applicability. The discovery [2]
and recognition of the epothilones as potent tubulin poly-
merizing agents [3] propelled them into the forefront of
chemical and biological research (for review see [4] and
references therein). Hailed as superior antitumor agents
to PTX, epothilones A (1) and B (2) (Figure 1) stimulated
several total syntheses [5^16] and construction of numer-
ous analogs with promising pharmacological pro¢les [4].
These studies [4] hinted at the importance of the nitrogen
of the side chain as well as of the macrocyclic scaffold and
its substituents for the biological activity of these mole-
cules. In this communication we report the design, chem-
ical synthesis and biological evaluation of a series of pyr-
idine epothilone B analogs which establish the crucial role
of these structural features for potent tubulin binding and
cytotoxicity. Remarkably, two of these new analogs proved
to be more potent against a variety of human cancer cell
lines than epothilone B, the most active of the naturally
occurring epothilones.
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Results and discussion
Molecular design and chemical synthesis of pyridine
epothilones
The molecular design of the reported epothilone analogs
(1^7, Figure 1) was based on (a) the fact that epothilone B
(Epo B) is considerably more potent than epothilone A
(Epo A); and (b) the assumption that the nitrogen atom
of the side chain needed to be at the strategic position that
is found in the natural epothilones. The pyridine ring
linked appropriately at the 2-position (analog 1) was chosen
as a substitute for the thiazole moiety. Molecular modeling
[17] strongly suggested a role of this nitrogen as a hydro-
gen bond acceptor within the tubulin binding site, and to
test this hypothesis the nitrogen atom was moved around
the pyridine nucleus as in analogs 6 and 7. To increase the
lipophilicity of the molecule, a methyl group was intro-
duced in the pyridine ring at all possible positions (analogs
2^5).
Figure 1. Molecular structures of Epo A and Epo B and designed pyridine epothilones B (1^7).
Scheme 1. Synthesis of designed pyridyl epothilones 1^7. Reagents and conditions: (a) TsCl (1.5 equiv), Et3N (3.0 equiv), 4-DMAP (1.0
equiv), CH2Cl, 0^25³C, 1 h; (b) NaI (3.0 equiv), acetone, 25³C, 15 h, 75% (2 steps); (c) NaBH3CN (10.0 equiv), DMPU, 45³C, 40 h, 70%;
(d) PdCl2(MeCN)2 (0.5 equiv), CuI (2.0 equiv), AsPh3 (1.0 equiv), 13a^g (2.5 equiv), DMF, 25³C, 1 h, 52^73%. Ts = p-toluenesulfonyl;
4-DMAP = 4-dimethylaminopyridine, DMPU = N,NP-dimethylpropyleneurea. 7: Rf = 0.71 (silica gel, ethyl acetate); [K]22D 377.5 (c 1.3, CHCl3);
IR (thin ¢lm) Xmax 3441, 2930, 1735, 1682, 1600, 1460, 1376, 1260, 1148, 1054 cm31; 1H NMR (600 MHz, CDCl3) N 8.35 (d, J = 4.8 Hz,
1H, ArH), 7.08 (s, 1H, ArH), 6.95 (d, J = 4.8 Hz, 1H, ArH), 6.56 (s, 1H, CHNCCH3), 5.38 (bs, 1H, CHOH), 5.35 (dd, J = 9.6, 1.8 Hz, 1H,
CH2COOCH), 4.38^4.32 (m, 1H, CHOH), 3.74^3.70 (m, 1H, CHOH), 3.29^3.24 (m, 1H, C(O)CH(CH3)), 2.92 (bs, 1H, OH), 2.78 (dd,
J = 8.8, 3.5 Hz, 1H, CHOCCH3), 2.49 (dd, J = 13.2, 11.0 Hz, 1H, CH2COOCH), 2.35 (s, 3H, ArCH3), 2.31 (m, 1H), 2.25 (dd, J = 13.2, 2.6
Hz, 1H, CH2COOCH), 2.20^2.14 (m, 1H, (CH3)COCHCH2CHO), 2.02 (s, 3H, CHNCCH3), 1.88 (s, 3H, C(CH3)OCHCH2), 1.78^1.70 (m,
2H, CH2C(CH3)OCH), 1.64^1.56 (m, 1H), 1.54^1.40 (m, 3H), 1.32^1.28 (m, 1H), 1.26 (s, 3H, C(CH3)2), 1.13 (d, J = 6.6 Hz, 3H, CH(CH3),
1.05 (s, 3H, C(CH3)2), 0.97 (d, J = 7.0 Hz, 3H, CH3CHCHOH); 13C NMR (150.9 MHz, CDCl3) N 220.7, 170.7, 155.2, 148.7, 147.8, 140.8,
125.1, 124.7, 122.6, 76.3, 71.5, 62.2, 61.7, 60.3, 53.9, 39.6, 36.1, 32.9, 32.3, 30.7, 22.5, 22.1, 21.7, 21.1, 20.9, 17.7, 16.8, 15.8, 14.1;
MALDI HRMS (DHB) m/z 524.2983, M+Na calcd. for C29H43NO6 524.2988.
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The designed pyridine epothilones 1^7 were synthesized
via a convergent approach as outlined in Scheme 1. The
strategy [18,19] involved palladium-catalyzed coupling
(Stille coupling) (for a recent review see [20]) of a common
precursor, vinyl iodide 11 [19], with the appropriate pyridyl
stannanes (13a^g, Scheme 2) providing directly the tar-
geted compounds. Thus, the previously synthesized epo-
thilone intermediate 8 [19] was selectively converted to
tosylate 9 (TsCl, Et3N), and thence to iodide 10 (NaI,
75% overall yield for two steps). The latter compound
(10) was reduced with NaBH3CN to afford the desired
vinyl iodide 11 in 70% yield. The required pyridyl stan-
nanes 13a^g were prepared from the corresponding, com-
mercially available, bromopyridines 12a^g (Scheme 2) via
metal^halogen exchange (nBuLi) followed by quenching
with nBu3SnCl (40^89% yield, unoptimized). The Stille
coupling of vinyl iodide 11 with stannanes 13a^g pro-
ceeded smoothly in the presence of PdCl2(MeCN)2, CuI
and AsPh3 to afford epothilone analogs 1^7 in 52^73%
yield (unoptimized) as shown in Scheme 1. The newly
synthesized analogs were chromatographically puri¢ed (sili-
ca gel) and fully characterized by spectroscopic means (see
legend of Scheme 1).
Molecular modeling
The pyridine analogs of epothilones were docked into the
pharmacophore-re¢ned tubulin model previously described
[17]. Brie£y, constrained molecular mechanics minimiza-
tions using the class II force ¢eld (CVFF91) were per-
formed on acceptable pyridine conformers. The conform-
ers that were considered acceptable had no van der Waals
overlap with tubulin atoms above 0.25 Aî , after rotations
were performed in 3‡ increments, about the C15^C16 tor-
sion. These rotatable bonds were explored until a full 360‡
rotation was completed. The C16^C17 and C17^C18
bonds were planar to the pyridine rings due to conjugation
and support through PM3 semiempirical calculations. Pyr-
idine conformers with nitrogens that were not solvent-ex-
posed were rejected. Acceptable conformers were ex-
tended to include the cis and trans isomers of the 16-
methyl substituent relative to the solvent-accessible sur-
face of tubulin. These docking studies were performed
for both wild-type (1A9) and mutant tubulin models
(PTX10, A8, and B10) where deemed appropriate based
on biological activity.
Biological evaluation
The synthesized epothilones were screened for their abil-
ity to induce in vitro tubulin polymerization using the ¢l-
tration colorimetric assay (see Materials and methods Sec-
tion) and Epo B was retested for comparison purposes.
This analysis was then followed by cytotoxicity studies in
a set of ovarian carcinoma cell lines, including a parental
cell line (1A9) and four drug-resistant cell lines, namely
two paclitaxel-resistant cell lines (1A9/PTX10 and 1A9/
Table 1
Biological properties of pyridine epothilones 1a.
Compound % TPa Inhibition of ovarian carcinoma cell growth (IC50) (nM)b
Parental L-Tubulin mutant cells
1A9 PTX10 (L270) PTX22 (L364) A8 (L274) B10 (L282)
Epo B 98 0.2 0.6 (3)c 0.2 (1) 5.4 (25) 5.2 (24)
1 79.5d 0.1 1 (10) 0.15 (1.5) 3 (30) 5 (50)
2 0 s 300 s 300 s 300 s 300 s300
3 90.3d 0.1 0.36 (3.6) 0.1 (1) 2.5 (25) 5 (50)
4 92 0.15 0.6 (4) 0.15 (1) 1.5 (10) 4 (27)
5 45 9 72 (8) 18 (2) 180 (20) 270 (30)
6 41.7d 1.7 35 (20) 8 (4.7) 23 (14) 10.5 (6)
7 34.5d 5.75 180 (31) 25 (4) 38 (6.6) 20 (3.4)
aThe in vitro tubulin polymerization assay (% TP), the cytotoxicity assay and the origin and characteristics of the cell lines used are de-
scribed in the Materials and methods Section.
bIC50 values in nM represent the average of one to three independent 96-h growth inhibition assays. IC50 is de¢ned as the drug concentra-
tion that reduced cell protein by 50%.
cValues in parentheses are fold resistance factors, de¢ned as the IC50 value obtained for the L-tubulin mutant divided by that obtained for
the parental line.
dThe percent tubulin polymerization values were calculated according to the method described in Table 2.
Scheme 2. Preparation of pyridine stannanes 13a^g. Reagents
and conditions: (a) nBuLi (1.1 equiv), THF, 378³C, 1 h, then add
nBu3SnCl (1.2 equiv), 378^25³C, 1 h, 40^89%.
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PTX22) [21] and two epothilone-resistant cell lines (1A9/
A8 and 1A9/B10) [17] (see Table 1). These resistant cell
lines harbor distinct acquired L-tubulin mutations which
affect drug^tubulin interaction and result in impaired tax-
ane- and epothilone-driven tubulin polymerization. In the
atomic model of KL-tubulin, these mutations are located
near the taxane binding site [22]. The results of these
biological investigations are summarized in Table 1 and
reveal some important information for the structure^activ-
ity relationship of these compounds.
In general, there is good agreement between the in vitro
tubulin polymerization potency and the cytotoxicity pro¢le
of all compounds tested. Interestingly, three compounds
(1, 3 and 4) were more potent in the cell growth inhibition
assay against the parental 1A9 cells than Epo B, the most
active of the naturally occurring epothilones. All three com-
pounds retained a cross-resistance pro¢le similar to Epo B
against the four taxol- and Epo B-resistant cell lines reveal-
ing that substitution of the thiazole ring by a pyridine
moiety (compound 1) or with a 4- or 5-methylpyridine
system (compounds 3 and 4) is bene¢cial for biological
activity (see below). Similarly to the thiazole side chain
of Epo B, the presence of the nitrogen at the speci¢c
location shown is crucial for the interaction with tubulin
as it, presumably, serves as a hydrogen bond acceptor. The
fact that a similar cytotoxicity pro¢le was obtained against
the L-tubulin mutants potentially indicates that the confor-
mation of these modi¢ed epothilones (1, 3 and 4) does not
change upon binding to tubulin so that the same groups
that are important for Epo B binding remain instrumental
for the interaction of these compounds with tubulin. In
addition, compound 4 was more active than Epo B or com-
pound 3 against the Epo-resistant 1A9/A8 cell line (fold
resistance factors: 25 for Epo B and compound 3, and 10
for compound 4) that harbors the L274Thr!ILe mutation.
This result suggests that the 5-methylpyridine system of
compound 4 interacts more favorably with the hydrogen-
bonded solvent network mediated by Ile at position L274.
Compound 2 was inactive both in vitro (0% tubulin poly-
merization) and in cells (IC50s 300 nM), i.e. placement of
a methyl group at the 3-position of the pyridine ring results
in total loss of activity. One possible explanation for this
behavior is that the methyl group at the 3-position of the
pyridine moiety forces the ring into an out-of-plane con-
formation with the neighboring double bond which is ap-
parently unfavorable for binding to tubulin. Finally, com-
pound 5 was much less potent than the parent Epo B, both
in vitro and in cells, suggesting that the 6-methylpyridine
substitution also leads to unfavorable changes in drug^tu-
bulin interaction. The importance of the location of the
nitrogen at the side chain was addressed by moving the
nitrogen atom at two different positions on the pyridine
ring. Molecular modeling predicted that the best position
for the nitrogen atom would be the ortho position while
relocation to the meta (compound 6) or para (compound
7) position would produce a signi¢cant loss of activity,
with the rank order of activity being orthosmetas para.
This prediction was experimentally con¢rmed by both the
in vitro tubulin polymerization and the cytotoxicity assay.
As shown in Table 1, compound 6 is 17-fold less active
against the 1A9 parental cells as compared to compound 1
which has the nitrogen at the ortho position (IC50 values,
1.7 and 0.1 nM, respectively) while compound 7 is 57.5-
fold less active than compound 1 (IC50 values, 5.75 and
0.1 nM, respectively).
Table 2
Biological properties of pyridine epothilones. 2
Compound % TPb Cell growth inhibition of PTX-sensitive and PTX-resistant human cancer cell lines (IC50) (nM)a
Epidermoidc Lungd Colone Prostatef Breastg
KB-31 KB-8511 A549 NCIH460 HCT-15 HCT-116 DU-145 PC3-M MCF-7 MCF-7/ADR
Epo B 85 0.18 0.18 (1)h 0.26 0.3 0.45 0.31 0.33 0.52 0.16 3.32 (20)
1 79.5 0.304 0.3 (1) 0.53 0.37 0.46 0.57 0.51 0.76 0.24 5.3 (22)
2 12 39.3 50.5 (1.28) nd nd nd nd nd nd nd nd
3 90.3 0.16 0.16 (1) 0.2 0.23 0.34 0.37 0.3 0.43 0.14 3.02 (21)
4 89.3 0.11 0.1 (1) 0.13 0.18 0.19 0.27 0.24 0.35 0.12 1.25 (10)
5 29.7 9.052 10.58 (1.17) 8.9 8.16 14.48 12.33 20.2 nd 7.07 nd
6 41.7 4.32 16.5 (3.8) nd nd nd nd nd nd nd nd
7 34.5 11.8 34.7 (2.94) nd nd nd nd nd nd nd nd
PTX 43.5 2.29 545.7 (238) 3.25 5.71 136.2 2.79 2.79 4.19 1.85 8984 (5005)
aThe cytotoxicity assay and the calculation of IC50 values is described in the Materials and methods Section.
bThe in vitro tubulin polymerization assay (% TP) is described in the Materials and methods Section.
cKB-31, PTX-sensitive, KB-8511, PTX-resistant due to P-gp overexpression, subline of KB-31.
dA549, NCIH460, PTX-sensitive.
eHCT-15, partially PTX-resistant due to P-gp overexpression, HCT-116, PTX-sensitive.
fDU-145, PC3-M, PTX-sensitive.
gMCF-7, PTX-sensitive, MCF-7/ADR, PTX-resistant due to P-gp overexpression, subline of the MCF-7 cell line.
hValues in parentheses are fold resistance factors de¢ned as the IC50 value obtained for the drug-resistant subline divided by that obtained
for the parental line.
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The biological properties of the synthesized epothilones
were also evaluated in a panel of human cancer cell lines
of distinct origin as summarized in Table 2. In this table
there are some cell lines resistant to PTX due to overex-
pression of P-gp. The cross-resistance pro¢le of pyridine
epothilones against the P-gp overexpressing cell lines sug-
gests that they are far less favorable substrates for P-gp
than PTX. For example PTX is 5000-fold less active
against MCF-7/ADR cells as compared to parental MCF-
7 cells, while Epo B and compounds 1, 3, and 4 are only
10^22-fold less active. Moreover, Epo B and compounds
1^7 retain almost full activity against the KB-8511 cells, in
contrast to PTX which is 238-fold less active in this cell
line compared to the parental KB-31 cells. In addition, the
results of Table 2 show that compounds 3 and 4 are con-
sistently more potent that the parent Epo B against the
panel of the 10 human cancer cell lines tested, while com-
pound 1 appears to be less potent in most cell lines. Sim-
ilarly to the results presented in Table 1, compounds 6 and
7 are 14^39-fold less active than compound 1 against KB-
31 cells, thus reinforcing the idea that the best placement
for the nitrogen atom of the pyridine side chain is ortho to
the attachment point of the ethenyl linker bridging the two
ring domains of the epothilone structure.
The biological data for these pyridine epothilones are con-
sistent with molecular docking experiments of these com-
pounds within the common taxane-epothilone binding site
according to our recently developed model of the interac-
tions of Epo B with the energy-re¢ned tubulin structure
[17]. Figure 2 depicts compound 4 bound to its receptor
site and surrounded by residues L-V21, L-F270 and
L-T274. Noteworthy is the lipophilic extension of this
compound provided by the 5-methyl substituent and
which reaches closer to the lipophilic pocket formed by
the L-V21 residue leading to enhanced interaction (higher
potency). This binding mode provides the basis for the
structure activity relationship of analogs 1^7 by our dock-
ing studies.
For example, according to the model of compound 1, the
unsubstituted pyridine is bulkier than the thiazole of Epo
B. The model also indicates that this region of the taxane
binding site is sterically restricted in such a way that the
pyridine must occupy a conformation that is essentially
Figure 2. Stick model of compound 4 (carbon atoms in yellow) docked into an energy-re¢ned model of tubulin. The backbone ribbon
structure of tubulin is green. Arrows point at two residues that confer taxane and epothilone resistance (L270 and L274) and at one
residue (L21) that makes a favorable hydrophobic contact with the 5-methyl group of the pyridine ring of compound 4.
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perpendicular to the solvent interface with tubulin. Such a
conformation renders the pyridine nitrogen of 1 to be com-
pletely solvent-exposed which serves to facilitate hydrogen
bonding with solvent. This modeling also indicates that
the pyridine nitrogen that is ortho to the ring junction
would be the only position on the pyridine where this
hydrogen bond acceptor is completely solvent-exposed.
The docking of compound 6 where the nitrogen of the
pyridine is meta relative to the ring junction indicates
that the nitrogen would be only partially accessible to
the solvent. This prediction was con¢rmed with the
marked decrease in activity of compound 6. In addition,
moving the pyridine nitrogen to the para position (as in
compound 7) further reduced the activity of this com-
pound. This was predicted by docking studies of com-
pound 7 due to the complete inaccessibility of the pyridine
nitrogen of 7 to solvent.
Our modeling studies also indicate that the preferred con-
formation of the pyridine with the ole¢n group attached to
carbon 18 is planar. This is supported by the docked con-
formation of compound 2, where the methyl group at po-
sition 3 of the pyridine ring forces this ring out of plane
with the ole¢n attached to 18. In this model, the entire
side chain of 2 is parallel to the solvent-accessible surface
of tubulin. This is a highly unfavorable binding mode, as
the hydrophobic constituents of the pyridine ring are for
the most part solvent-exposed. On the other hand, placing
a methyl group at the 4-position of the pyridine ring (as in
compound 3) enables the pyridine^C16^C17 ole¢n system
to form a planar conformation and make favorable hydro-
phobic contacts with the side chain of Ala231. However,
similar to 1, the extra bulk from the pyridine and methyl
substituents imposes a steric restriction that shifts the en-
tire molecule, including the macrolide ring system, approx-
imately 1.0 Aî away from the Epo B binding mode into the
hydrogen-bonded network coordinated by Arg282 and
Thr274. This may explain the increased sensitivity to
both the epothilone-selected mutants A8 (L274) and B10
(L282) for compounds 1 and 3. This result is consistent
with the docking study of compound 4. The placement
of a methyl group onto pyridine, para to the ring junction
(as in 4), has the opposite effect of the 4-methyl substitu-
ent in 3, or the absence of the methyl group in 1. The
most important effect of this change is that the 5-methyl
group of compound 4 increases the overall length of the
epothilone pyridine structure. As a consequence, 4 reposi-
tions itself away from the Phe270 which results in the
7-OH group of the macrolide being 1.28 Aî away from
Epo B’s hydrogen-bonded solvent network, which is coor-
dinated by Arg282 and Thr274. This model also indicates
that 4 still retains its solvent-mediated hydrogen bond with
Thr274. This may explain why 4 is more active against the
A8 and B10 mutant cells compared to 1 and 3.
Our modeling also explains the loss of activity of com-
pound 5. Docking shows that its 6-methyl group of the
pyridine is exposed to solvent which creates a signi¢cantly
less favorable binding mode, and decreases at the same
time the solvent accessibility of this pyridine nitrogen. In
concert with the repositioning of the pyridine nitrogen (as
in compounds 6 and 7), the previous ¢nding underscores
the notion that a six-membered ring requires a strong hy-
drogen bond acceptor in this solvent-exposed portion,
when bound to tubulin.
In summary, we have identi¢ed two compounds (3 and 4)
with superior biological activity over the parent Epo B, the
most potent of the naturally occurring epothilones. Com-
pound 4, in particular, shows increased activity against the
epothilone-resistant cell line A8 with a L274 tubulin muta-
tion and is the most active of all the compounds tested
against the P-gp overexpressing cell line MCF-7/ADR.
Signi¢cance
In conclusion, we have designed and synthesized a series
of pyridine Epo B analogs, and established, through bio-
logical investigations and molecular modeling, the impor-
tance of the presence and location of the nitrogen for tu-
bulin binding and cytotoxicity in these compounds. Most
signi¢cantly, we have discovered that two of the newly
synthesized pyridine epothilones exhibit more potent cy-
totoxic effects than Epo B against a wide variety of human
cancer cells, including PTX- and Epo B-resistant cells.
These ¢ndings are expected to aid further chemical biol-
ogy studies and drug discovery efforts in the ¢eld of cancer
chemotherapy.
Materials and methods
In vitro tubulin polymerization assay (Table 1)
Tubulin polymerization was determined by the ¢ltration^colorimetric as-
say as previously described [3]. Brie£y, 1 mg/ml of puri¢ed tubulin was
incubated at 37³C for 30 min with 5 WM of each compound in MEM
buffer [100 mM 2-(N-morpholino)ethanesulfonic acid, pH 6.75, 1 mM
ethylene glycol bis(L-aminoethyl ether)-N,N,NP,NP-tetraacetic acid, 1 mM
MgCl2]. The mixture was then ¢ltered to remove unpolymerized tubulin
in a 96-well ¢ltration plate (pore size, 0.22 Wm) and the collected poly-
merized tubulin was stained with amido black solution and quanti¢ed by
measuring absorbance of the dyed solution on a microplate reader. The
percent polymerization was calculated relative to the absorbance pro-
duced by incubation with 0.5 M GTP+10% glycerol in MEM (presumed
to cause 100% polymerization).
In vitro tubulin polymerization assay (Table 2)
Induction of tubulin polymerization was determined using a modi¢ed
version of the microtubule protein centrifugation assay, as previously
described [24]. MAP-associated porcine brain tubulin was incubated
with 2 WM compound for 20 min. Percentage numbers indicate the rel-
ative degree of polymerization as compared to 25 WM Epo B, which
under our experimental conditions caused s95% of the total tubulin
to polymerize.
Cell culture and cytotoxicity assay (Table 1)
The epothilone-resistant cell lines 1A9/A8 and 1A9/B10 were isolated in
a single step following exposure of the human ovarian carcinoma cell
line A2780 (1A9) to lethal (IC99) concentrations of either Epo A or B
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(IC99 concentrations: 6 nM for Epo A and 0.5 nM for Epo B). After an
initial expansion, the concentration of epothilones in the culture medium
was gradually increased to 30 nM for Epo A and 5 nM for Epo B [17].
The isolation and characterization of the PTX-resistant cell lines 1A9/
PTX10 and 1A9/PTX22 has been described elsewhere [21]. Cells were
maintained in a 5% CO2 humidi¢ed atmosphere at 37³C in RPMI me-
dium 1640 (Gibco BRL) containing 10% fetal bovine serum, penicillin
(100 U/ml) and streptomycin (100 Wg/ml) (Gibco BRL). Prior to an ex-
periment the 1A9/PTX10, 1A9/PTX22, 1A9/A8 and 1A9/B10 cells were
cultured for at least 7^10 days in drug-free medium. Cytotoxicity assays
were performed in 96-well plates using the sulforhodamine B assay as
described previously [23] by seeding 500 cells/well and incubating with
cytotoxic agents for 4 days.
Cytotoxicity assay (Table 2)
Antiproliferative assays were performed as previously described [25].
Brie£y, cells were seeded at 1.5U103/well into 96-well microtiter plates
and incubated overnight. Compounds were added in serial dilutions on
day 1. Subsequently, the plates were incubated for two population dou-
blings (3^5 days) and then ¢xed with 3.3% v/v glutaraldehyde, washed
with water and stained with 0.05% methylene blue. After washing, the
dye was eluted with 3% v/v HCl and the optical density measured
at 665 nm with a SpectraMax 340 (Bucherer, Basel, Switzerland).
IC50 values were determined by a computerized system (Softpro,
Bucherer, Basel, Switzerland) using the formula (ODtreated3ODstart)/
(ODcontrol3ODstart)U100. IC50 is de¢ned as the drug concentration
which leads to 50% of cells per well as compared to control cultures
(100%) at the end of the incubation period. The data represent the mean
of three independent experiments.
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